“The current condition has uncovered some structural weaknesses in the EU’s medicines offer chain and a superior dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides said. She suggested that supply chain issues be dealt with within an EU pharmaceutical tac